Schrödinger, Inc. (NASDAQ:SDGR) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET

Company Participants

Ramy Farid - President and CEO
Geoff Porges - CFO
Karen Akinsanya - President R&D, Therapeutics
Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications

Conference Call Participants

Michael Yee - Jefferies
David Leibowitz - Citi
Scott Schoenhaus - KeyBanc
Vikram Purohit - Morgan Stanley
Conor McKay - BMO
Steven Mah - TD Cowen
Michael Ryskin - Bank of America
Matthew Hewitt - Craig-Hallam Capital
Joseph Catanzaro - Piper Sandler
Chris Shibutani - Goldman Sachs

Operator

Welcome to Schrödinger's Conference Call to review First Quarter and 2024 Financial Results. My name is Claudette [ph], and I will be your operator for today's call. Please be advised that this call is being recorded at the company's request.

Now I would like to introduce your host for today's conference, Miss. Jaren Madden, Director of Investor Relations and Corporate Affairs. Please go ahead.

Jaren Madden

Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our first quarter and 2024 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com.

Here with me on our call today are Ramy Farid, Chief Executive Officer; Geoff Porges, Chief Financial Officer and Karen Akinsanya, President of R&D, Therapeutics. Following our prepared remarks, we'll open the call for Q&A. During today's call, management will make statements that are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation statements related to our outlook for the second quarter and full year 2024, our plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of, initiation of, and readouts from our clinical trials, the clinical potential and properties of our compounds.

The use of our cash resources, and our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made.

Actual results may differ materially due to a number of important factors, including the considerations described in the risk factors section and elsewhere in the filings we make with the SEC, including our Form 10-Q for the quarter ended March 31, 2024. These forward-looking statements represent our views only as of today and we caution you that, except as required by law, we may not update them in the future, whether as a result of new information, future events, or otherwise. Also included in today's call are certain non-GAAP financial measures.